A Phase 3 interventional study of E/C/F/TAF and TDF in HIV-1 Infection, sponsored by Gilead Sciences. Completed at 35 sites in 5 countries. Open to participants aged 60 Years and older. Per ClinicalTrials.gov, last updated 2020-03-04.
Sponsored by Gilead Sciences · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The primary objective of this study is to evaluate the safety of elvitegravir/cobicistat/emtricitabine/ tenofovir alafenamide (E/C/F/TAF) relative to unchanged current antiretroviral therapy (ART) by assessing spine and hip bone mineral density (BMD) measured at Week 48 in virologically-suppressed, HIV-1 infected participants aged ≥ 60 years.
Gilead Sciences is the lead sponsor of 692 studies on the registry; 26 are open to participants now.
Of its 261 completed or terminated interventional studies of FDA-regulated products, 251 (96%) have results posted.
Counted across the registry records on this site, refreshed daily.
Key Inclusion Criteria:
Refer to assigned interventions for allowed third agents of the current regimen.
Key Exclusion Criteria:
Note: Other protocol defined Inclusion/ Exclusion criteria may apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CD4 count
The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will switch from tenofovir disoproxil fumarate (TDF) and emtricitabine (FTC) or 3TC plus a third agent to E/C/F/TAF and will receive treatment for 48 weeks.
Drug: E/C/F/TAF
Participants will remain on current TDF and FTC (or FTC/TDF) or 3TC plus continuing third agent.
Drug: TDF · Drug: FTC · Drug: FTC/TDF · Drug: 3TC · Drug: Third agent
Drug pages: Elvitegravir · Cobicistat · Emtricitabine · Tenofovir alafenamide
150/150/200/10 mg FDC tablet administered orally once daily
Also known as: Genvoya®
300 mg tablet administered orally once daily
Also known as: Viread®
200 mg capsule administered orally once daily
Also known as: Emtriva®
200/300 mg tablet administered orally once daily
Also known as: Truvada®
Tablet administered orally
Also known as: Lamivudine, Epivir®
Third agent may include one of the following regimens: lopinavir+ritonavir (LPV/r; Kaletra®), atazanavir (ATV; Reyataz®) + ritonavir (RTV; Norvir®), ATV + cobicistat (COBI;Tybost®) (or ATV/COBI FDC), DRV + RTV, darunavir (DRV; Prezista®) + COBI (or DRV/COBI FDC), fosamprenavir (FPV; Lexiva®) + RTV , saquinavir (SQV; Invirase®; Fortovase®) + RTV, efavirenz (EFV;Sustiva®), rilpivirine (RPV;Edurant®), nevirapine (NVP;Viramune®), etravirine (ETR;Intelence®), raltegravir (RAL; Isentress®), elvitegravir (EVG) + COBI, or dolutegravir (DTG;Tivicay®) Drug classes: * Protease inhibitors (PI): LPV/r, ATV, RTV, ATV, DRV, FPV, and SQV * Pharmacokinetic enhancer: COBI * Non-nucleoside reverse transcriptase inhibitors (NNRTI): EFV, RPV, NVP, and ETR * Integrase inhibitors: RAL and DTG
Percent Change From Baseline to Week 48 in Spine BMD
Time frame: Baseline; Week 48
Percent Change From Baseline to Week 48 in Hip BMD
Time frame: Baseline; Week 48
Percent Change From Baseline to Week 24 in Spine BMD
Time frame: Baseline; Week 24
Percent Change From Baseline to Week 24 in Hip BMD
Time frame: Baseline; Week 24
Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 24 as Defined by the US FDA-Defined Snapshot Algorithm
The percentage of participants with HIV-1 RNA \< 50 copies/mL at Week 24 was analyzed using the snapshot algorithm, which defines a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status.
Time frame: Week 24
Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 48 as Defined by the US FDA-Defined Snapshot Algorithm
The percentage of participants with HIV-1 RNA \< 50 copies/mL at Week 48 was analyzed using the snapshot algorithm, which defines a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status.
Time frame: Week 48
Change From Baseline in CD4+ Cell Count at Week 24
Time frame: Baseline; Week 24
Change in Baseline in CD4+ Cell Count at Week 48
Time frame: Baseline; Week 48
Participants were enrolled at study sites in Europe. The first participant was screened on 22 December 2015. The last study visit occurred on 21 March 2018.
| Milestone | E/C/F/TAF | Stay on Baseline Regimen |
|---|---|---|
| Started | 111 | 56 |
| Completed | 105 | 54 |
| Not completed | 6 | 2 |
| Withdrew: Randomized but not treated | 1 | 0 |
| Withdrew: Adverse event | 1 | 0 |
| Withdrew: Death | 1 | 0 |
| Withdrew: Non-compliance with study drug | 1 | 0 |
| Withdrew: Protocol violation | 1 | 1 |
| Withdrew: Withdrew consent | 1 | 1 |
| Percent change | E/C/F/TAF | Stay on Baseline Regimen |
|---|---|---|
| Percent Change From Baseline to Week 48 in Spine BMD | 2.237 ± 3.2727 | -0.104 ± 3.3854 |
| Percent change | E/C/F/TAF | Stay on Baseline Regimen |
|---|---|---|
| Percent Change From Baseline to Week 48 in Hip BMD | 1.330 ± 2.1968 | -0.726 ± 3.2069 |
| Percent change | E/C/F/TAF | Stay on Baseline Regimen |
|---|---|---|
| Percent Change From Baseline to Week 24 in Spine BMD | 1.625 ± 3.2346 | -0.027 ± 2.9875 |
| Percent change | E/C/F/TAF | Stay on Baseline Regimen |
|---|---|---|
| Percent Change From Baseline to Week 24 in Hip BMD | 0.808 ± 1.9084 | -0.537 ± 2.7647 |
The percentage of participants with HIV-1 RNA \< 50 copies/mL at Week 24 was analyzed using the snapshot algorithm, which defines a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status.
| Percentage of participants | E/C/F/TAF | Stay on Baseline Regimen |
|---|---|---|
| Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 24 as Defined by the US FDA-Defined Snapshot Algorithm | 94.5 | 100.0 |
The percentage of participants with HIV-1 RNA \< 50 copies/mL at Week 48 was analyzed using the snapshot algorithm, which defines a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status.
| Percentage of participants | E/C/F/TAF | Stay on Baseline Regimen |
|---|---|---|
| Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 48 as Defined by the US FDA-Defined Snapshot Algorithm | 93.6 | 94.5 |
| cells/μL | E/C/F/TAF | Stay on Baseline Regimen |
|---|---|---|
| Change From Baseline in CD4+ Cell Count at Week 24 | 48 ± 161.9 | -4 ± 153.9 |
| cells/μL | E/C/F/TAF | Stay on Baseline Regimen |
|---|---|---|
| Change in Baseline in CD4+ Cell Count at Week 48 | 56 ± 177.7 | -1 ± 149.1 |
Collected over Up to 48 weeks plus 30 days. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| E/C/F/TAF | 1/110 (0.9%) | 10/110 (9.1%) | 47/110 (42.7%) |
| Stay on Baseline Regimen | 0/56 (0%) | 1/56 (1.8%) | 20/56 (35.7%) |
| Event | E/C/F/TAF | Stay on Baseline Regimen |
|---|---|---|
| Acute coronary syndromeCardiac disorders | 1/110 | 1/56 |
| Cardiac arrestCardiac disorders | 1/110 | 0/56 |
| Cholecystitis acuteHepatobiliary disorders | 1/110 | 0/56 |
| Escherichia sepsisInfections and infestations | 1/110 | 0/56 |
| PneumoniaInfections and infestations | 1/110 | 0/56 |
| SepsisInfections and infestations | 1/110 | 0/56 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 1/110 | 0/56 |
| Joint swellingMusculoskeletal and connective tissue disorders | 1/110 | 0/56 |
| OsteonecrosisMusculoskeletal and connective tissue disorders | 1/110 | 0/56 |
| Colorectal cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/110 | 0/56 |
| Event | E/C/F/TAF | Stay on Baseline Regimen |
|---|---|---|
| NasopharyngitisInfections and infestations | 12/110 | 3/56 |
| BronchitisInfections and infestations | 4/110 | 6/56 |
| Back painMusculoskeletal and connective tissue disorders | 9/110 | 2/56 |
| DiarrhoeaGastrointestinal disorders | 8/110 | 2/56 |
| Vitamin D deficiencyMetabolism and nutrition disorders | 7/110 | 4/56 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 6/110 | 4/56 |
| HypertensionVascular disorders | 7/110 | 1/56 |
| CoughRespiratory, thoracic and mediastinal disorders | 6/110 | 0/56 |
| Urinary tract infectionInfections and infestations | 4/110 | 3/56 |
Safety Analysis Set included all participants who were randomized into the study and received at least 1 dose of study drug.
| Age, Continuous(Years) | E/C/F/TAF | Stay on Baseline Regimen | Total |
|---|---|---|---|
| Mean | 65 ± 4.6 | 66 ± 4.9 | 66 ± 4.7 |
| Sex: Female, Male(Participants) | E/C/F/TAF | Stay on Baseline Regimen | Total |
|---|---|---|---|
| Female | 14 | 5 | 19 |
| Male | 96 | 51 | 147 |
| Ethnicity (NIH/OMB)(Participants) | E/C/F/TAF | Stay on Baseline Regimen | Total |
|---|---|---|---|
| Hispanic or Latino | 16 | 8 | 24 |
| Not Hispanic or Latino | 88 | 42 | 130 |
| Unknown or Not Reported | 6 | 6 | 12 |
| Race/Ethnicity, Customized(Participants) | E/C/F/TAF | Stay on Baseline Regimen | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 1 | 1 |
| Black or African American | 2 | 2 | 4 |
| White | 103 | 49 | 152 |
| Not Permitted | 5 | 4 | 9 |
| Region of Enrollment(Participants) | E/C/F/TAF | Stay on Baseline Regimen | Total |
|---|---|---|---|
| Belgium | 8 | 1 | 9 |
| Italy | 36 | 15 | 51 |
| United Kingdom | 8 | 3 | 11 |
| France | 29 | 23 | 52 |
| Spain | 29 | 14 | 43 |
| HIV-1 RNA Category(Participants) | E/C/F/TAF | Stay on Baseline Regimen | Total |
|---|---|---|---|
| < 50 copies/mL | 109 | 56 | 165 |
| ≥ 50 copies/mL | 1 | 0 | 1 |
| CD4+ Cell Count(cells/µL) | E/C/F/TAF | Stay on Baseline Regimen | Total |
|---|---|---|---|
| Mean | 649 ± 255.6 | 676 ± 316.5 | 658 ± 277.0 |
| CD4+ Cell Count Category(Participants) | E/C/F/TAF | Stay on Baseline Regimen | Total |
|---|---|---|---|
| ≥ 50 to < 200 cells/µL | 0 | 2 | 2 |
| ≥ 200 to < 350 cells/µL | 12 | 8 | 20 |
| ≥ 350 to < 500 cells/µL | 18 | 7 | 25 |
| ≥ 500 cells/µL | 80 | 39 | 119 |
2 further baseline measures are reported on the registry.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Qualified external researchers may request IPD for this study after study completion. For more information, please visit our website at https://www.gilead.com/science-and-medicine/research/clinical-trials-transparency-and-data-sharing-policy.
Supporting information: Study protocol, Statistical analysis plan
Time frame: 18 months after study completion
Access criteria: A secured external environment with username, password, and RSA code.
Data sharing details ↗ · www.gilead.com
Ran from Dec 2015 to primary completion in Feb 2018, 25 months.
Results were first posted in Feb 2019, 11 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Elvitegravir · Cobicistat · Emtricitabine · Tenofovir alafenamide